OUR PURPOSE IS SIMPLE:
Patients fighting chronic diseases are often denied access to life-saving treatments.
ICERWatch gives patients a voice to fight back.
Patients living with migraine need access to effective treatments. ICER has begun its process of evaluating treatments for acute migraine.
The Institute for Clinical and Economic Review (ICER) is floating a power grab at the Food and Drug Administration to deny patients access to innovation.
Thousands of young boys living with Duchenne Muscular Dystrophy, a rare and fatal disease, could be denied access to treatment, due to a new ICER report.
We have an important message for ICER: Patients are not a number. Patients living with depression and multiple sclerosis have the same right to access treatments as anyone else.
An obscure health care cost evaluator could deliver a devastating blow to patients living with multiple sclerosis this week, as it evaluates a promising new
As the draft report notes, “the quality of life outcomes for the phase 3 trials have not yet been published. It is [therefore] challenging to fully evaluate the impact of these therapies without placebo-controlled assessments of the change in quality of life.” Given the reality of such limited data – particularly about patient perspectives and quality – we believe it is too early for ICER to conduct this assessment.